Drug intelligence / Profile preview

INF-001

Development stage: Preclinical
Lead developer: Omic

Overview

INF-001 is a preclinical-stage drug candidate being developed by Omic Analytics for the treatment of HIV. Discovered using the company's AI-driven drug discovery platform, the program specifically targets the HIV latent reservoir with the objective of achieving a functional cure. While the specific biological target and modality (e.g., small molecule or biologic) remain undisclosed, the program focuses on novel therapeutic mechanisms to address HIV latency, which remains a primary obstacle to eradicating the virus and achieving a cure.

Beyond the preview

Go deeper on INF-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INF-001.

Explore the full profile